Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Nash

Showing results (61-70 of 198) with videos related to

Pageof 20
Sort By:
Annals of the Rheumatic Diseases|August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsChristina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Rheumatology and Therapy|December 17, 2024
Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational StudyPeter C Taylor, Walid Fakhouri, Samuel Ogwu, et al.
Journal of Comparative Effectiveness Research|September 20, 2018
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysisIain B McInnes, Peter Nash, Christopher Ritchlin, et al.
Rheumatology and Therapy|April 2, 2018
Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect ComparisonPeter Nash, Iain B McInnes, Philip J Mease, et al.
Rheumatology and Therapy|June 23, 2019
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 StudyAlan J Kivitz, Peter Nash, Hasan Tahir, et al.
Pathology|November 23, 2012
Cellular blue naevus involving the urinary bladderJennifer Kim, Stanley W McCarthy, John F Thompson, et al.
Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.
Rheumatology and Therapy|June 3, 2018
Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect ComparisonPeter Nash, Iain B McInnes, Philip J Mease, et al.
Journal of Medical Imaging and Radiation Oncology|August 4, 2020
Chemical shift imaging in the identification of those renal tumours that contain microscopic fat and the utility of multiparametric MRI in their differentiationSuresh de Silva, Kathleen Lockhart, Peter Aslan, et al.
BMC Urology|April 23, 2021
The diagnostic utility of diffusion weighted MRI imaging and ADC ratio to distinguish benign from malignant renal masses: sorting the kittens from the tigersSuresh de Silva, Kathleen Rebecca Lockhart, Peter Aslan, et al.
Pageof 20

Showing results (61-70 of 198) with videos related to

Sort By:
Pageof 20
Annals of the Rheumatic Diseases|August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugsChristina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Rheumatology and Therapy|December 17, 2024
Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational StudyPeter C Taylor, Walid Fakhouri, Samuel Ogwu, et al.
Journal of Comparative Effectiveness Research|September 20, 2018
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysisIain B McInnes, Peter Nash, Christopher Ritchlin, et al.
Rheumatology and Therapy|April 2, 2018
Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect ComparisonPeter Nash, Iain B McInnes, Philip J Mease, et al.
Rheumatology and Therapy|June 23, 2019
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 StudyAlan J Kivitz, Peter Nash, Hasan Tahir, et al.
Pathology|November 23, 2012
Cellular blue naevus involving the urinary bladderJennifer Kim, Stanley W McCarthy, John F Thompson, et al.
Arthritis and Rheumatism|June 10, 2004
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trialJ Peter Kaltwasser, Peter Nash, Dafna Gladman, et al.
Rheumatology and Therapy|June 3, 2018
Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect ComparisonPeter Nash, Iain B McInnes, Philip J Mease, et al.
Journal of Medical Imaging and Radiation Oncology|August 4, 2020
Chemical shift imaging in the identification of those renal tumours that contain microscopic fat and the utility of multiparametric MRI in their differentiationSuresh de Silva, Kathleen Lockhart, Peter Aslan, et al.
BMC Urology|April 23, 2021
The diagnostic utility of diffusion weighted MRI imaging and ADC ratio to distinguish benign from malignant renal masses: sorting the kittens from the tigersSuresh de Silva, Kathleen Rebecca Lockhart, Peter Aslan, et al.
Pageof 20